

Inclusion

Age \geq 18 years old

ECOG 0 or 1

Locally advanced, unresectable or metastatic non-squamous NSCLC not eligible for curative surgery and/or definitive chemoradiotherapy

No prior treatment for metastatic disease and treatment-free interval of 12 months for curative/definitive treatment of non-metastatic disease

Availability of tumor specimens in FFPE blocks or \geq 15 slides (patients with 10-14 slides may be eligible with Medical Monitor approval)

PD-L1 status by local sp263 or local 22c3 or central sp263 (if acceptable local test unavailable) must be known prior to enrollment

If central assessment of ALK/EGFR status is required, an additional 5 slides must be submitted
Measurable disease per RECIST v1.1

Negative test for HIV; negative serology for active HBV or HCV

Patients must have adequate hematology and end-organ function, defined by the following laboratory results, within 14 days of C1D1:

ANC \geq 1.5 $\times 10^9$ /L (1500/uL)

Lymphocyte count \geq 0.5 $\times 10^9$ /L (500/uL)

Platelet count \geq 100 $\times 10^9$ /L (100,000/uL) without transfusion

Hemoglobin \geq 90 g/L (9 g/dL) 1

INR or aPTT \leq 1.5 \times ULN2

AST, ALT, and ALP \leq 2.5 \times ULN3

Total bilirubin \leq 1.5 \times ULN4

Creatinine Clearance \geq 40 mL/min (\geq 60 mL/min for cisplatin)

Albumin \geq 25 g/L (2.5 g/dL)